Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study

Journal of Clinical Oncology

Volumn 32, Issue 27, 2014, Pages 2951-2958

  Sabine, Vicky S ^a   Crozier, Cheryl ^a   Brookes, Cassandra L ^c   Drake, Camilla ^a   Piper, Tammy ^b   Van De Velde, Cornelis J H ^h   Hasenburg, Annette ^d   Kieback, Dirk G ^e   Markopoulos, Christos ^f   Dirix, Luc ^g   Seynaeve, Caroline ⁱ   Rea, Daniel W ^c   Bartlett, John M S ^a,b  

^a ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF FREIBURG   (Germany)

^e HELIOS Medical Center   (Germany)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^g SINT AUGUSTINUS HOSPITAL   (Belgium)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EXEMESTANE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TAMOXIFEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DNA; PIK3CA PROTEIN, HUMAN; TUMOR MARKER;

AKT GENE; ARTICLE; BRAF GENE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE; GENE MUTATION; HRAS GENE; HUMAN; HUMAN CELL; KRAS GENE; MUTATIONAL ANALYSIS; NRAS GENE; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PIK3CA GENE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; ADULT; AGED; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ADULT; AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84907208070     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.8272     Document Type: Article

References (37)

1. Peto R: Early Breast Cancer Trialists' Collaborative Group. The worldwide overview: New results for systemic adjuvant therapies. Presented at the 30th Annual San Antonio Breast Cancer Symposium, December 13-16, 2007, San Antonio, TX
2. World Health Organisation: WHO Mortality database. http://www.who.int/healthinfo/mortality-data/en/
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 378: 771-784, 2011
4. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70, 2012
5. Forbes SA, Bindal N, Bamford S, et al: COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39: D945-D950, 2011 (database issue)
6. Saini KS, Loi S, de Azambuja E, et al: Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev 39: 935-946, 2013
7. Bartlett JM: Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: Current status and future directions. Clin Breast Cancer 10: S86-S95, 2010 (suppl 3)
8. Burke JE, Perisic O, Masson GR, et al: Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110a (PIK3CA). Proc Natl Acad Sci U S A 109: 15259-15264, 2012
9. Zhao L, Vogt PK: Class I PI3K in oncogenic cellular transformation. Oncogene 27: 5486-5496, 2008
10. Gymnopoulos M, Elsliger MA, Vogt PK: Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A 104: 5569-5574, 2007
11. Dannemann N, Hart JR, Ueno L, Vogt PK: Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic. Int J Cancer 127: 239-244, 2010
12. Janku F, Lee JJ, Tsimberidou AM, et al PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers PLoS One 6: e22769, 2011
13. Castellano E, Downward J: RAS interaction with PI3K: More than just another effector pathway. Genes Cancer 2: 261-274, 2011
14. Kalinsky K, Jacks LM, Heguy A, et al PIK3CA mutation associates with improved out-come in breast cancer. Clin Cancer Res 15: 5049-5059, 2009
15. Ramirez-Ardila DE, Helmijr JC, Look MP, et al: Hotspot mutations in PIK3CA associate with firstline treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Res Treat 139: 39-49, 2013
16. Hortobagyi G, Piccart M, Rugo H, et al: Genetic alterations and everolimus efficacy in hormone receptor-positive, HER-2-negative advanced breast cancer: Preliminary correlative results from BOLERO-2. J Clin Oncol 31: 9s, 2013 (suppl; abstr LBA509)
17. Ciruelos E, Cortes-Funes H, Ghanem I, et al: Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer. Anticancer Drugs 24: 769-780, 2013
18. Di Nicolantonio F, Arena S, Tabernero J, et al: Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120: 2858-2866, 2010
19. Spears M, Cunningham CA, Taylor KJ, et al: Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression. J Pathol 227: 481-489, 2012
20. Sabine V, Sims A, Macaskill E, et al: Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer. Breast Cancer Res Treat 122: 419-428, 2010
21. Satheesha S, Cookson VJ, Coleman LJ, et al: Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer. Mol Cancer 10: 19-28, 2011
22. Lai YL, Mau BL, Cheng WH, et al: PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol 15: 1064-1069, 2008
23. Barbareschi M, Buttitta F, Felicioni L, et al: Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 13: 6064-6069, 2007
24. Loi S, Haibe-Kains B, Majjaj S, et al: PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 107: 10208-10213, 2010
25. Bartlett JM, Brookes CL, Robson T, et al: Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: A prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 29: 1531-1538, 2011
26. van de Velde CJ, Rea D, Seynaeve C, et al: Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomised phase 3 trial. Lancet 377: 321-331, 2011
27. Board RE, Thelwell NJ, Ravetto PF, et al: Multiplexed assays for detection of mutations in PIK3CA. Clin Chem 54: 757-760, 2008
28. Bartlett JM, Brookes CL, Piper T, et al: Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial. Br J Cancer 109: 2453-2461, 2013
29. Christiansen J, Bartlett JM, Gustavson, et al: Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches. J Clin Oncol 30: 11s, 2012 (suppl; abstr 517)
30. Collett D: Modelling Survival Data in Medical Research. London, UK, Chapman & Hall, 1994, p79
31. Lee CK, Brown C, Gralla RJ, et al: Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis. J Natl Cancer Inst 105: 595-605, 2013
32. Wang L, Zhang Q, Zhang J, et al: PI3K pathway activation results in low efficacy of both trastu-zumab and lapatinib. BMC Cancer 11: 248-257, 2011
33. Miller TW, Rexer BN, Garrett JT, et al: Mutations in the phosphatidylinositol 3-kinase pathway: Role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13: 224-235, 2011
34. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366: 520-529, 2011
35. Cheng L, Zhang S, MacLennan GT, et al: Bladder cancer: Translating molecular genetic insights into clinical practice. Hum Pathol 42: 455-481, 2011
36. Choudhury AD, Eeles R, Freedland SJ, et al: The role of genetic markers in the management of prostate cancer. Eur Urol 62: 577-587, 2012
37. Stephens PJ, Tarpey PS, Davies H, et al: The landscape of cancer genes and mutational processes in breast cancer. Nature 486: 400-404, 2012